UBS Oncology Impact Fund L.P.
CIK 1691428 · last filed 2023-06-05
UBS Oncology Impact Fund L.P. is a corporate insider who has filed 33 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for HOWL, was dated Jul 6, 2026. Across all open-market trades the lifetime net is −$38.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $111.3M across reported positions. The firm reports its address in Boston, MA. 66 SEC filings were submitted jointly with MPM BioImpact LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1100
BOSTON, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,515,075 | $10.15 | $45.83M | -$91.36M | 6 | 2022-01-06 |
| CGEM | 10%+ Owner | 7,657,817 | $14.54 | $111.34M | -$1.48M | 2 | 2021-09-16 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 1,037,659 | $23.01 | $23.88M | $5.15M | 3 | 2021-05-17 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 1,525,348 | $0.12 | $183.9K | $9.07M | 1 | 2020-10-08 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 3,370,982 | $1.48 | $4.99M | $40.00M | 1 | 2019-02-21 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | HOWL | Notice (144) | −80,142 | -$27.3K | EDGAR |
| 2026-06-29 | HOWL | Notice (144) | −87,916 | -$28.4K | EDGAR |
| 2026-05-28 | HOWL | Notice (144) | −202,029 | -$99.0K | EDGAR |
| 2026-05-18 | HOWL | Notice (144) | −240,280 | -$123.8K | EDGAR |
| 2026-05-11 | HOWL | Notice (144) | −69,904 | -$47.5K | EDGAR |
| 2026-05-01 | HOWL | Notice (144) | −300,821 | -$216.5K | EDGAR |
| 2026-04-29 | HOWL | Notice (144) | −107,652 | -$79.7K | EDGAR |
| 2026-04-27 | HOWL | Notice (144) | −107,652 | -$87.5K | EDGAR |
| 2026-01-06 | HOWL | Notice (144) | −164,126 | -$105.8K | EDGAR |
| 2025-12-29 | HOWL | Notice (144) | −107,463 | -$70.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.